New Glaucoma Treatment Effective in Trial

Wednesday, 25 Jun 2014 12:15 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Drug developer Aerie Pharmaceuticals Inc said its single-drop eye treatment was shown to be superior to each of its two components in a mid-stage trial, sending its shares up by about 24 percent in premarket trading.
The drug, Roclatan, combines Aerie's other experimental glaucoma drug Rhopressa with the approved latanoprost.
Patients treated with the drug experienced a significant reduction in fluid pressure inside the eye, compared with those treated with either latanoprost or Rhopressa.
Glaucoma is a condition in which increased eye pressure could damage the optic nerve and lead to blindness, if left untreated.
Aerie Pharma said it would immediately start preparing for Roclatan's late-stage trial.
It is also preparing to start a late-stage trial for Rhopressa early in the third quarter.
 

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

Seniors Have Harder Time Coping With Distractions: Study

Saturday, 26 Jul 2014 08:59 AM

Seniors are more easily distracted during thinking and memory tasks than younger people, a new study finds.
Almost . . .

9 in 10 Adults Eat Everything on Their Plate

Friday, 25 Jul 2014 16:34 PM

Unlike children, the vast majority of adults finish all of the food they put on their plate at mealtime, according to a  . . .

Sleeping in Total Darkness Boosts Breast Cancer Therapy: Study

Friday, 25 Jul 2014 16:26 PM

Tulane University researchers have found dim light at night can compromise the effectiveness of the breast cancer drug t . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved